Sens. Durbin and Cassidy Introduce REMEDY Act to Lower Drug Costs by Ending Patent Loopholes
The REMEDY Act is currently in the early stages of the legislative process. It was introduced in the Senate and is now being reviewed by the Committee on Health, Education, Labor, and Pensions. There are no upcoming votes scheduled at this time.
While the bill has strong bipartisan support from influential senators, it faces intense opposition from the powerful pharmaceutical lobby which often stalls such changes in committee.
This bill’s path across every version that has carried it.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Small business owners who provide health insurance to employees face high prescription drug costs that drive up premiums. Faster generic drug entry for future medications could modestly reduce prescription spending in employer health plans over time, easing the insurance cost burden on small employers.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5000)
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Senators Dick Durbin and Bill Cassidy reintroduced the REMEDY Act to tackle pharmaceutical 'evergreening.' The bill aims to lower costs by removing barriers to FDA approval for generics, specifically narrowing the 30-month stay to a single, manufacturer-selected patent.
Senator Bill Cassidy co-introduced the REMEDY Act to require drugmakers to identify a single patent for the 30-month stay. The move comes as the FTC investigates patent abuses that delay generic competition, with Cassidy seeking clearer FDA guidance on Orange Book listings.
The REMEDY Act, reintroduced in July 2025, seeks to limit innovators to only one Orange Book-listed patent eligible for the 30-month stay. This 'One Patent' rule would force companies to designate their strongest patent in advance, curbing the use of serial litigation as a stalling tactic.
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
REMEDY Act
Analysis generated by AI. Always verify with official sources.